Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

This study examined symptom trajectories and predictors of high symptom burden in 64 multiple myeloma (MM) patients during 16 weeks of induction therapy. Nearly one-third experienced persistent moderate-to-severe symptoms, including pain, muscle weakness, numbness, disturbed sleep, and fatigue. High symptom severity predicted worse quality of life and functioning, with female sex linked to increased muscle weakness risk. These findings underscore the need for proactive symptom management in MM care.